331 related articles for article (PubMed ID: 11535987)
1. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers in epithelial ovarian cancer].
Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
[TBL] [Abstract][Full Text] [Related]
3. [Tumour markers in epithelial ovarian cancer].
Sparholt MH; Høgdall E; Høgdall CK
Ugeskr Laeger; 2009 Nov; 171(48):3505-9. PubMed ID: 19944049
[TBL] [Abstract][Full Text] [Related]
4. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
5. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
6. A step forward for two-step screening for ovarian cancer.
Hensley ML
J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
[No Abstract] [Full Text] [Related]
7. [Tumor marker in ovarian cancer].
Komai K; Nishida T
Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744
[TBL] [Abstract][Full Text] [Related]
8. [Ovarian neoplasms and tumor markers].
Zarcone R; Candido R; Cardone G; De Luca P; Voto RI; Bellini P
Minerva Ginecol; 1994 Oct; 46(10):531-3. PubMed ID: 7838408
[TBL] [Abstract][Full Text] [Related]
9. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
10. [Interest of CA 125 level in management of ovarian cancer].
Coussy F; Chéreau E; Daraï E; Dhombres F; Lotz JP; Rouzier R; Selle F
Gynecol Obstet Fertil; 2011 May; 39(5):296-301. PubMed ID: 21515085
[TBL] [Abstract][Full Text] [Related]
11. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
Petignat P; Vajda D; Obrist R
Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
[TBL] [Abstract][Full Text] [Related]
12. Personalizing ovarian cancer screening.
Goozner M
J Natl Cancer Inst; 2010 Aug; 102(15):1112-3. PubMed ID: 20668268
[No Abstract] [Full Text] [Related]
13. [Application of multi-tumor markers in ovarian carcinoma].
Feng J; Qian H; Tian Y
Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
[No Abstract] [Full Text] [Related]
15. [Expression of CA-125 in ovarian cancer].
Mircea R; Frîncu DL; Dumitrache F
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
[TBL] [Abstract][Full Text] [Related]
16. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
17. CA-125: a biomarker put to the test.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
[No Abstract] [Full Text] [Related]
18. [Screening for ovarian cancers: critical analysis].
Pennehouat G; Gugliemina JN; Naouri M; Créquat J; Bouret JM; Thébault Y; Madelenat P
Contracept Fertil Sex; 1993 Mar; 21(3):223-30. PubMed ID: 7951617
[TBL] [Abstract][Full Text] [Related]
19. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
